EMA reminds pharma of post-Brexit continuity - for now

31 January 2020

ema_conference-room-xl_credit_rob-acket_large

On the day that the UK leaves the European Union (EU), the European Medicines Agency (EMA) has reminded drugmakers that any major changes will not be seen for another 11 months.

Although the UK will become a third country to the EU on Saturday, a transition period will continue until December 31, 2020.

During this period, EU pharmaceutical law will remain applicable in the UK, and companies have until 2021 to make the necessary changes to ensure that their authorized medicines comply with EU law and can remain on the EU market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK